Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
107 participants
OBSERVATIONAL
2010-12-31
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Natural History and Pathogenesis of Alopecia in Children and Adults
NCT05502796
Topical Crisaborole in Patients with Alopecia Areata
NCT04299503
Pharmacogenomic Study of Androgenetic Alopecia
NCT01227031
Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants
NCT02812342
Clinical Trial of Safety and Efficacy of Daily Application of Topical Dutasteride in Men With Androgenic Alopecia.
NCT05599243
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Population: 120 patients aged 20-64 with Fabry disease that have GLA mutations or alpha-galactosidase A activity associated with no residual enzyme activity and non-Fabry male controls of the same age range and the same number of non-Fabry controls.
Design: This is a cross-sectional study comparing the prevalence of androgenic alopecia in two groups of subjects.
Outcome Measures: The levels of the outcome will be no androgenic alopecia and frontal only androgenetic alopecia opposed to vertex only and frontal and vertex androgenetic alopecia.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with the classic form
No interventions assigned to this group
Fabry disease and healthy controls
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy male controls age 20-64 years old
* GLA gene mutations associated with the classic form of Fabry disease or having alpha-galactosidase A activity that is essentially zero
* Patients who freely agree to participate in this study and understand the nature, risks and benefits of this study and give their written informed consent.
18 Years
64 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Baylor Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Raphael Schiffmann, MD
Role: PRINCIPAL_INVESTIGATOR
Baylor Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Baylor University Medical Center
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
010-308
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.